These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

544 related articles for article (PubMed ID: 29045526)

  • 1. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1/PD-L1+ tumors.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Ann Oncol; 2017 Dec; 28(12):2977-2984. PubMed ID: 29045526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIM-3 expression in breast cancer.
    Burugu S; Gao D; Leung S; Chia SK; Nielsen TO
    Oncoimmunology; 2018; 7(11):e1502128. PubMed ID: 30377566
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes.
    He Y; Yu H; Rozeboom L; Rivard CJ; Ellison K; Dziadziuszko R; Suda K; Ren S; Wu C; Hou L; Zhou C; Hirsch FR
    J Thorac Oncol; 2017 May; 12(5):814-823. PubMed ID: 28132868
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The combined presence of CD20 + B cells and PD-L1 + tumor-infiltrating lymphocytes in inflammatory breast cancer is prognostic of improved patient outcome.
    Arias-Pulido H; Cimino-Mathews A; Chaher N; Qualls C; Joste N; Colpaert C; Marotti JD; Foisey M; Prossnitz ER; Emens LA; Fiering S
    Breast Cancer Res Treat; 2018 Sep; 171(2):273-282. PubMed ID: 29858752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immune stratification reveals a subset of PD-1/LAG-3 double-positive triple-negative breast cancers.
    Bottai G; Raschioni C; Losurdo A; Di Tommaso L; Tinterri C; Torrisi R; Reis-Filho JS; Roncalli M; Sotiriou C; Santoro A; Mantovani A; Loi S; Santarpia L
    Breast Cancer Res; 2016 Dec; 18(1):121. PubMed ID: 27912781
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of the immune checkpoint VISTA in breast cancer.
    Zong L; Mo S; Yu S; Zhou Y; Zhang M; Chen J; Xiang Y
    Cancer Immunol Immunother; 2020 Aug; 69(8):1437-1446. PubMed ID: 32266446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of immune checkpoints expression and lymphocyte densities of iranian breast cancer patients; the co-expression status and clinicopathological associates.
    Pournabee M; Keshavarz-Fathi M; Esmaeili P; Mahdavi Sharif P; Nili F; Jahanbin B
    BMC Cancer; 2023 Jun; 23(1):495. PubMed ID: 37264298
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune Checkpoint Markers in Superficial Angiosarcomas: PD-L1, PD-1, CD8, LAG-3, and Tumor-Infiltrating Lymphocytes.
    Googe PB; Flores K; Jenkins F; Merritt B; Moschos SJ; Grilley-Olson JE
    Am J Dermatopathol; 2021 Aug; 43(8):556-559. PubMed ID: 33156018
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lymphocyte-activating gene-3 expression is associated with tumor-infiltrating lymphocyte levels in HER2-positive breast cancers.
    Lee S; Kim JY; Lee SJ; Kwon SW; Jung HJ; Jung SJ; Kim KB; Choi KU; Lee CH; Huh GY; Kim A
    Medicine (Baltimore); 2021 Dec; 100(50):e28057. PubMed ID: 34918659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and Clinicopathologic Associations of LAG-3 Expression in Triple-negative Breast Cancer.
    Stovgaard ES; Kümler I; List-Jensen K; Roslind A; Christensen IJ; Høgdall E; Nielsen D; Balslev E
    Appl Immunohistochem Mol Morphol; 2022 Jan; 30(1):62-71. PubMed ID: 34081635
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the tumor immune microenvironment phenotypes in different breast cancers after neoadjuvant therapy.
    Han M; Li J; Wu S; Wu C; Yu Y; Liu Y
    Cancer Med; 2023 Feb; 12(3):2906-2917. PubMed ID: 36073303
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of HIV Status With Local Immune Response to Anal Squamous Cell Carcinoma: Implications for Immunotherapy.
    Yanik EL; Kaunitz GJ; Cottrell TR; Succaria F; McMiller TL; Ascierto ML; Esandrio J; Xu H; Ogurtsova A; Cornish T; Lipson EJ; Topalian SL; Engels EA; Taube JM
    JAMA Oncol; 2017 Jul; 3(7):974-978. PubMed ID: 28334399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis.
    Duchnowska R; Pęksa R; Radecka B; Mandat T; Trojanowski T; Jarosz B; Czartoryska-Arłukowicz B; Olszewski WP; Och W; Kalinka-Warzocha E; Kozłowski W; Kowalczyk A; Loi S; Biernat W; Jassem J;
    Breast Cancer Res; 2016 Apr; 18(1):43. PubMed ID: 27117582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer.
    Park IH; Kong SY; Ro JY; Kwon Y; Kang JH; Mo HJ; Jung SY; Lee S; Lee KS; Kang HS; Lee E; Joo J; Ro J
    Clin Breast Cancer; 2016 Feb; 16(1):51-8. PubMed ID: 26364145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metaplastic breast cancers frequently express immune checkpoint markers FOXP3 and PD-L1.
    Kalaw E; Lim M; Kutasovic JR; Sokolova A; Taege L; Johnstone K; Bennett J; Saunus JM; Niland C; Ferguson K; Gresshoff I; Bettington M; Pathmanathan N; Tse GM; Papadimos D; Pathmanathan R; Harris G; Yamaguchi R; Tan PH; Fox S; O'Toole SA; Simpson PT; Lakhani SR; McCart Reed AE
    Br J Cancer; 2020 Nov; 123(11):1665-1672. PubMed ID: 32939056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
    Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
    BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High ratio of programmed cell death protein 1 (PD-1)(+)/CD8(+) tumor-infiltrating lymphocytes identifies a poor prognostic subset of extrahepatic bile duct cancer undergoing surgery plus adjuvant chemoradiotherapy.
    Lim YJ; Koh J; Kim K; Chie EK; Kim B; Lee KB; Jang JY; Kim SW; Oh DY; Bang YJ; Ha SW
    Radiother Oncol; 2015 Oct; 117(1):165-70. PubMed ID: 26235847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.